LLY · 10-Q · 2026Q3 · Full report

Product Launch - Foundayo

ELI LILLY & Co · 2026-10-29 · Importance 34 · Surprise 42

Lilly launched Foundayo (orforglipron) in the U.S. in the second quarter of 2026 for obesity treatment and submitted it to the FDA for type 2 diabetes. Internationally, the company has submitted or launched orforglipron for obesity and/or type 2 diabetes in all major markets. The company also launched Mounjaro internationally.

Key facts

• Lilly launched Foundayo in the U.S. in the second quarter of 2026 for treatment of obesity and submitted orforglipron to the FDA for type 2 diabetes. source
• Lilly submitted orforglipron for type 2 diabetes in the U.S. and Japan. source